Back to top

gene-therapy: Archive

Zacks Equity Research

SRPT Beats on Q3 Earnings & Sales, Discontinues PPMO-Based DMD Program

Sarepta posts encouraging Q3 earnings. After conducting a risk-benefit analysis, the company decides to stop developing the entire PPMO program.

BIIBNegative Net Change FOLDNegative Net Change SRPTPositive Net Change

Zacks Equity Research

CRSP's Q3 Loss Narrower Than Expected, Sales Miss Estimates

CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.

BIIBNegative Net Change VRTXNegative Net Change FOLDNegative Net Change CRSPNegative Net Change

Zacks Equity Research

CRISPR Therapeutics to Report Q3 Earnings: Is a Beat in Store?

On CRSP's third-quarter 2024 earnings call, investors will likely focus on the sales numbers of its recently approved gene therapy, Casgevy.

REGNPositive Net Change PFEPositive Net Change VRTXNegative Net Change CRSPNegative Net Change

Zacks Equity Research

EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down

Editas stock falls on a decision to seek a partner for its lead gene-therapy candidate, reni-cell, for SCD and TDT and focus resources on in vivo pipeline development.

VRTXNegative Net Change ANIPNegative Net Change FATENegative Net Change EDITNegative Net Change